{"title":"贫血和心血管并发症:铁和促生成素的影响。","authors":"N A Kurtzman, S Sabatini","doi":"10.1159/000057431","DOIUrl":null,"url":null,"abstract":"<p><p>Management of end-stage renal disease (ESRD) has been revolutionized by the advent of erythropoietin replacement. We briefly review its characteristics and clinical use. Also emphasized is the importance of iron deficiency in limiting the clinical response to erythropoietin therapy. Iron-replacement therapy in ESRD patients is briefly discussed.</p>","PeriodicalId":18722,"journal":{"name":"Mineral and electrolyte metabolism","volume":"25 1-2","pages":"109-13"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000057431","citationCount":"1","resultStr":"{\"title\":\"Anemia and cardiovascular complications: iron and EPO impact.\",\"authors\":\"N A Kurtzman, S Sabatini\",\"doi\":\"10.1159/000057431\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Management of end-stage renal disease (ESRD) has been revolutionized by the advent of erythropoietin replacement. We briefly review its characteristics and clinical use. Also emphasized is the importance of iron deficiency in limiting the clinical response to erythropoietin therapy. Iron-replacement therapy in ESRD patients is briefly discussed.</p>\",\"PeriodicalId\":18722,\"journal\":{\"name\":\"Mineral and electrolyte metabolism\",\"volume\":\"25 1-2\",\"pages\":\"109-13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000057431\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mineral and electrolyte metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000057431\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mineral and electrolyte metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000057431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anemia and cardiovascular complications: iron and EPO impact.
Management of end-stage renal disease (ESRD) has been revolutionized by the advent of erythropoietin replacement. We briefly review its characteristics and clinical use. Also emphasized is the importance of iron deficiency in limiting the clinical response to erythropoietin therapy. Iron-replacement therapy in ESRD patients is briefly discussed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
